Authors: Gillespie, AM Broadhead, TJ Chan, SY Owen, J Farnsworth, AP Sopwith, M Coleman, RE

Citation: Am. Gillespie et al., Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer, ANN ONCOL, 11(6), 2000, pp. 735-741

Authors: Davies, Q Perkins, AC Roos, JC Molthoff, CFM Verheijen, RHM Frier, M Kenemans, P Broadhead, T Sopwith, M Symonds, EM

Citation: Q. Davies et al., An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma, BR J OBST G, 106(1), 1999, pp. 31-37

Authors: Choy, EHS Rankin, ECC Kassimos, D Vetterlein, O Garyfallos, A Ravirajan, CT Sopwith, M Eastell, R Kingsley, GH Isenberg, DA Panayi, GS

Citation: Ehs. Choy et al., The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis, J RHEUMATOL, 26(11), 1999, pp. 2310-2317